Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity Back February 17, 2025 by admin Document https://www.nejm.org/doi/full/10.1056/NEJMoa2410027?query=TOC&ssotoken=U2FsdGVkX18N2NfOQJaQ5x%2FQ5vThzxb4u29SLd%2BdfgiO9VirpxebjbQiQsxDkrAXNJACRrhlNK4waOZRgTMe23x%2FUl8xdxOh6Xaf6VphU7X85GVTEh398sV6%2FhlDJkW3IutlJD84bXyW%2BQaRABQj9CDemgluiQdvlbzN6lUGGyGTep96OSwI20B0P0AQ8mdFHT7YutojHkT1e0JN6Rcu2g%3D%3D&cid=DM2384078_Non_Subscriber&bid=-1519047293 Metadata SubjectTirzepatide for Heart Failure with Preserved Ejection Fraction and ObesityTypeArticleTitleTirzepatide for Heart Failure with Preserved Ejection Fraction and ObesityDescriptionArticleLanguageEnglishSourceThe new England journal of medicineContributorMilton Packer, M.D., R. Zile, M.D., Christopher M. Kramer, M.D., Seth J. Baum, M.D., Sheldon E. Litwin, M.D., Venu Menon, M.D., Junbo Ge, M.D., Continue browsing HIV-Estimates-and-projection-for-the-year-2023-and-2024-EPHI-_Infectiouse-Disease-Research-Directorete-July052024 Continuation versus Interruption of Oral Anticoagulation during TAVI Back to items list